Long COVID RECOVER Study

Arizona Participant Town Hall Wednesday, September 27th







ACKNOWLEDGEMENTS

We thank all the participants enrolled in the RECOVER Initiative and their families and caregivers.

This research was funded by the NIH (OTA OT2HL161841, OT2HL161847, and OT2HL156812) as part of the Researching COVID to Enhance Recovery (RECOVER) research program and R01 HL162373.

~BL



Webinar Information

- There is time set for Q & A after the presentation of information
- Chat is available to send questions directly to the hosts and panelists
- Panelists will try to answer as many questions as possible
 - Panelists can answer questions about the research and the study
 - Panelists cannot provide a diagnosis




What we will talk about today

- RECOVER Observational Study overview and early findings
- RECOVER Trials what they are and where they stand
- What we are doing regarding Long COVID outside of RECOVER
- Your questions and future feedback



Panelists







Sairam Parthasarathy, MD MPI, RECOVER Study and RECOVER Clinical Trials Professor of Medicine Chief, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine



Joyce K. Lee-lannotti, MD PI, RECOVER Study Neurologist Associate Professor Neurology



Karen Lutrick, Ph.D
Co-Investigator, RECOVER
Study
Associate Professor and
Vice Chair of Research
Family & Community
Medicine
College of Medicine-Tucson



Kristen Pogreba-Brown, Ph.D.
Co-Investigator, RECOVER
Study
Associate Professor
Epidemiology and Biostatistics
Department
Mel and Enid Zuckerman
College of Public Health



~BL

Overview of RECOVER Observational Studies

And What We've Learned





What is RECOVER?

RECOVER stands for Researching COVID to Enhance Recovery.

It's a set of research studies that aim to learn about the longterm health effects of COVID.

observational studies, which means researchers collect information from participants. Participants will not get treatment for Long COVID in the observational studies. RECOVER clinical trials are just beginning.

Study Questions

- How many people are getting Long COVID?
- Why do some people get Long COVID and others do not?
- What symptoms do people feel when they get Long COVID?
- How long do people feel sick when they get Long COVID?
- Why does Long COVID happen?





RECOVER Observational Study Adult Cohort

- 14,880 participants who are 18 years of age and older and have reached the age of majority in their state of residence
- People who have had COVID (12,200): someone with a positive test showing they had an infection with the virus that causes COVID, or had symptoms that make us think they had COVID
 - People who never had COVID (2,680): someone who never had a
 positive test for COVID and never had any symptoms that make us
 think they had COVID







Adult Study Overview

Recruitment in 33 states; Washington, DC; Puerto Rico Diverse population with and without COVID-19

Adults/Pregnant people



Tier 1 Surveys, labs, biospecimens, minimal exam (14,880 participants)



Tier 2 Low-risk clinical tests (~4,000 participants per test)



Tier 3 Advanced Testing (~3,000 participants per test)







RECOVER Participation

- Consent forms allow people to choose their level of participation
- Surveys are completed every 3 months
- You may be selected for additional tests based on your symptoms or test results
- Some people will be randomly selected for some of the additional tests









RECOVER Adult Cohort Timeline

Post-Acute Cohort

(with infection before enrollment)

Includes pre-Omicron and Omicron variant as well as vaccinated and unvaccinated participants

Protocol developed with input from patients, patient reps, clinicians, and other scientists

Acute Cohort

(with infection around enrollment)
Almost exclusively Omicron variant
and vaccinated participants



February 2020 Beginning of COVID-19 pandemic in US December 2020

COVID-19 vaccines become available

December 2021

Omicron variant becomes dominant strain in the US Oct/Nov 2023 Expected

last participant enrolled in RECOVER Adult Cohort



October 2021 RECOVER Adult Cohort first participant enrolled Development of a
Definition of Postacute
Sequelae of SARS-CoV-2
Infection







What is Long COVID?

A condition in which a person has symptoms for weeks, months, or even years after a COVID infection.

New or ongoing symptoms, such as:



Feeling short of breath



Feeling very tired



Brain fog (feeling like you can't think clearly)



Cough

Problems with certain organs, such as:











Brain

It's estimated that:

76.5M

More than 76.5 million people in the US have Long COVID symptoms

Nearly 10% of people who get COVID experience symptoms of Long COVID for 6 months after infection



~JN recoverCOVID.org

RECOVER Adult Self-Reported Symptoms

Metabolic

Thirst

Dermatologic

Hair loss Skin color Skin pain Skin rash Eye, Ear, Nose, Throat

Hearing and Vision problems

Mouth pain Dry mouth

Respiratory

Chronic cough Short breadth

Gastrointestinal

Abdominal pain GI symptoms Throat pain

Musculoskeletal

Back pain Foot pain

Joint pain Muscle pain

Weakness

Neurologic

Abnormal movements
Loss/change smell/taste
Numbness/tingling
Unspecified nerve pain
Seizures

Cardiovascular

Chest pain
Palpitations
Swelling of legs

Urinary

Bladder

Brain Fog

Dizziness

Headache

Paralysis Tremor

Psychiatric

Anxiety

Depression

Reproductive

Pelvic/genital

Sexual capacity

General

Fatigue Fever/sweats/chills

Post-exertional Malaise

Unspecified pain Sleep disturbance




RECOVER Adult Cohort Study Design

Analysis cohort

- 1. Included participants with at least one visit 6 months or more after index date
- 2. Used first visit that occurs 6 months or more after index date

Cohort description

- 9,764 participants
- 71% female
- 16% Hispanic/Latino
- 15% non-Hispanic Black
- Median age 47 years
- 55% fully vaccinated before infection
- 41% first infection pre-Omicron





Publications

Your contributions to our study:

- Have led to over 40 published papers
- Are providing guidance for clinical trials
- Are the basis for over 250 more publications in the pipeline
- Were used to create a working definition of long COVID that was published in JAMA, June 2023
 - This article alone has been cited in over 500 news stories

JAMA | Original Investigation

Development of a Definition of Postacute Seguelae of SARS-CoV-2 Infection

Tanayott Thaweethal, PhD; Sarah E. Jolley, MD, MS; Elizabeth W. Karlson, MD, MS; Emily B. Levitan, ScD; Bruce Levy, MD; Grace A. McComsey, MD; Lisa McCorkell, MPP; Girish N. Nadkarni, MD, MPH; Sairam Parthasarathy, MD; Upinder Singh, MD; Tiffany A. Walker, MD; Caltlin A. Selvaggi, MS; Daniel J. Shinnick, MS; Carolin C. M. Schulte, PhD; Rachel Atchiey-Challenner, PhD; RECOVER Consortium Authors: Legra I. Horwitz, MD: Andrea S. Foulkes, ScD: for the RECOVER Consortium

IMPORTANCE SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and

OBJECTIVE To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections.

DESIGN, SETTING, AND PARTICIPANTS Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling.

MAIN OUTCOMES AND MEASURES PASC and 44 participant-reported symptoms (with severity thresholds).

RESULTS A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive

CONCLUSIONS AND RELEVANCE A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.

Editorial page 1918

Supplemental content



~//



Publications





Find RECOVER Publications

Researchers within the RECOVER Initiative are learning more about the long-term effects of COVID and they're sharing their progress through research publications. Follow the latest science from RECOVER as we discover more about how COVID affects people and what we can do to predict, treat, and prevent Long COVID. Visit the **Research Summaries** page to learn about the latest science from RECOVER in a format that is easy to understand.

Last updated: August 14, 2023



Resources

- Long COVID is complicated and there is still a lot to learn
- To understand why Long COVID develops, RECOVER is gearing up to do molecular analysis on samples that have been collected, and merge it with clinical data from your exams
- RECOVER has a YouTube channel with videos that have some more information about the study

QR Code for RECOVER YouTube channel















- HEALTH INFORMATION AND TRUST
- COVID-19
- LONG TERM ILLNESS
- LINGERING SYMPTOMS OF COVID INFECTION
- SOCIETAL FACTORS INFLUENCING HEALTH



IF YOU ARE INTERESTED OR WANT TO KNOW MORE, TEXT "JOIN" OR "ENROLL TO (844) 844 - 3004



An Institutional Review Board responsible for human subjects research at The University of Arizona reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.



Next Steps

Clinical Trials & Continuing Research





RECOVER VITAL

What is the study about?

RECOVER-VITAL is studying a possible treatment for people who have Long COVID. We want to learn if a study drug can reduce ongoing symptoms from the virus that causes COVID.

With your help, we can better understand why and how Long COVID affects people in different ways.

Am I a good fit for the study?

- You are an adult who had COVID
- You do not have an active COVID infection
- You still have 1 or more of these symptoms:
 - Exhaustion or low energy that interferes with daily activities
 - Trouble thinking clearly or brain fog
 - Dizziness, fast heart rate, shortness of breath, upset stomach, or other changes in body functions that happen automatically



<u>V</u>iral pers<u>i</u>stence and reac<u>t</u>ivation, and immune dysregulation



No health insurance is required.

Learn more at trials.recovercovid.org/vital





RECOVER NEURO

What is the study about?

RECOVER-NEURO is studying possible treatments for adults who have cognitive dysfunction symptoms related to Long COVID. We want to learn if brain training may improve those symptoms.

With your help, we can better understand why and how Long COVID affects people in different ways.

Am I a good fit for the study?

- You are an adult who had COVID
- You do not have an active COVID infection
- You have 1 or more of these symptoms:
 - Brain fog or trouble thinking clearly
 - Trouble paying attention or remembering things









RECOVER IS NOT ENOUGH.....

It was not meant, designed or funded to take care of people with Long COVID



National Centers of Excellence Strategy To Develop Evidence-Based Standards of Care For Long COVID Patients

• We are proposing a national Centers of Excellence (CoE) network to diagnose, treat, educate, and train on, Long COVID.

WHY?

- Long COVID is the next pandemic, we need money and resources to care for patients
- Unified & coordinated network needed to identify and disseminate best practices for Long COVID diagnosis, treatment, and care, implement the care and train the providers to do so.
- There is no federal, agency-, university-, or industry-proposed plan to solve this problem

ACCOMPLISHMENTS AND CURRENT STATE

- We (the Aegis consortium) are leading RECOVER Adult Site PI's to establish the Centers
- Developed a national CoE strategy that was included into the Senate appropriations language for FY24 (\$5M).
- Now raising awareness and federal & private fundraising, looking for patient partnerships



Next Steps

- What can we do to make your life better?
- Tell us your priorities, concerns, etc....
- Let's work and advocate for Long COVID together







For more information:

Email:

uahs-recover@arizona.edu

Phone:

(520) 621-8354





An Initiative Funded by the National Institutes of Health

recoverCOVID.org